• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    12/25/23 8:05:52 AM ET
    $ALVR
    $ATRA
    $BFRI
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALVR alert in real time by email

    Gainers

    • Karuna Therapeutics (NASDAQ:KRTX) shares increased by 47.4% to $317.1 during Monday's pre-market session. The company's market cap stands at $11.9 billion.
    • Universe Pharmaceuticals (NASDAQ:UPC) shares rose 30.21% to $1.55. The company's market cap stands at $5.6 million.
    • Senti Biosciences (NASDAQ:SNTI) shares rose 26.97% to $0.56. The company's market cap stands at $24.8 million.
    • Cidara Therapeutics (NASDAQ:CDTX) shares increased by 17.9% to $0.87. The company's market cap stands at $78.6 million.
    • Trinity Biotech (NASDAQ:TRIB) shares increased by 14.14% to $0.51. The company's market cap stands at $19.6 million.
    • Atara Biotherapeutics (NASDAQ:ATRA) stock moved upwards by 13.45% to $0.51. The market value of their outstanding shares is at $51.5 million.

    Losers

    • AlloVir (NASDAQ:ALVR) shares declined by 67.0% to $0.77 during Monday's pre-market session. The company's market cap stands at $87.8 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock declined by 37.5% to $2.25. The market value of their outstanding shares is at $1.8 million.
    • Castle Biosciences (NASDAQ:CSTL) shares fell 26.58% to $16.0. The market value of their outstanding shares is at $430.5 million.
    • 60 Degrees (NASDAQ:SXTP) stock fell 19.55% to $0.89. The market value of their outstanding shares is at $5.1 million.
    • Nanobiotix (NASDAQ:NBTX) shares fell 13.16% to $6.67. The market value of their outstanding shares is at $314.2 million.
    • Biofrontera (NASDAQ:BFRI) shares fell 12.39% to $2.83. The market value of their outstanding shares is at $4.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALVR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALVR
    $ATRA
    $BFRI
    $CDTX

    CompanyDatePrice TargetRatingAnalyst
    Nanobiotix S.A.
    $NBTX
    2/6/2026Buy
    TD Cowen
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Equal-Weight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Neutral
    Analyst
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Outperform → Sector Perform
    RBC Capital Mkts
    Cidara Therapeutics Inc.
    $CDTX
    10/16/2025$190.00Overweight
    Morgan Stanley
    Senti Biosciences Inc.
    $SNTI
    10/14/2025$12.00Buy
    H.C. Wainwright
    Cidara Therapeutics Inc.
    $CDTX
    10/10/2025$200.00Overweight
    Analyst
    More analyst ratings

    $ALVR
    $ATRA
    $BFRI
    $CDTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Stein Jeffrey disposed of $339,040 worth of shares (5,190 units at $65.33), bought $339,040 worth of shares (4,262 units at $79.55), gifted 1,873 shares and received a gift of 937 shares, decreasing direct ownership by 44% to 5,763 units (SEC Form 4)

    4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

    1/7/26 8:12:25 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Dow Geoffrey S bought $7,759 worth of shares (9,670 units at $0.80), increasing direct ownership by 19% to 59,618 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/16/25 5:41:35 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Dow Geoffrey S bought $12,204 worth of shares (12,963 units at $0.94), increasing direct ownership by 35% to 49,948 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/12/25 8:39:45 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVR
    $ATRA
    $BFRI
    $CDTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Nanobiotix

    TD Cowen initiated coverage of Nanobiotix with a rating of Buy

    2/6/26 8:11:18 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atara Biotherapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Atara Biotherapeutics from Buy to Hold and set a new price target of $6.00

    1/13/26 10:16:38 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cidara Therapeutics downgraded by RBC Capital Mkts

    RBC Capital Mkts downgraded Cidara Therapeutics from Outperform to Sector Perform

    11/17/25 9:39:33 AM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVR
    $ATRA
    $BFRI
    $CDTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Juvenal Tobin W covered exercise/tax liability with 14,115 shares and converted options into 25,771 shares, increasing direct ownership by 12% to 107,688 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    3/5/26 5:18:41 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Chief Operating Officer Oelschlager Kristen M covered exercise/tax liability with 9,219 shares and converted options into 25,771 shares, increasing direct ownership by 74% to 39,047 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    3/5/26 5:16:56 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Pres. & Chief Exec. Officer Maetzold Derek J covered exercise/tax liability with 36,974 shares and converted options into 59,097 shares, increasing direct ownership by 26% to 105,821 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    3/5/26 5:12:16 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $ALVR
    $ATRA
    $BFRI
    $CDTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

    FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma's i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity will be presented at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, being held March 5-7 in Phoenix. "The initial reports from the same prospective, multicenter study confirmed the performance of DecisionDx-Melanoma to both (i) impact sentinel lymph node biopsy (SLNB) decision-making and (ii) identify patients at low risk of nodal metastasis," said Rebecca Critchley-Thor

    3/4/26 4:30:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

    FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company's new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and other invited guests to commemorate the completion of the purpose-built facility. Local, state and national elected officials are expected to join the event, underscoring the significance of Castle's i

    3/3/26 4:30:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will present at the Leerink Partners 2026 Global Healthcare Conference in Miami, FL on Monday, March 9, 2026, at 2:20 PM ET. A webcast replay will be available on the Events page of the Investors section of the Company's website (sentibio.com). Interested parties may access the live video webcast here. About Senti Bio Senti Bio is a biotechnolog

    3/3/26 9:05:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVR
    $ATRA
    $BFRI
    $CDTX
    SEC Filings

    View All

    SEC Form 144 filed by Castle Biosciences Inc.

    144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    3/5/26 4:04:43 PM ET
    $CSTL
    Medical Specialities
    Health Care

    SEC Form EFFECT filed by Trinity Biotech plc

    EFFECT - TRINITY BIOTECH PLC (0000888721) (Filer)

    3/4/26 12:15:17 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Atara Biotherapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

    3/3/26 8:30:25 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVR
    $ATRA
    $BFRI
    $CDTX
    Leadership Updates

    Live Leadership Updates

    View All

    Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

    FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company's new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and other invited guests to commemorate the completion of the purpose-built facility. Local, state and national elected officials are expected to join the event, underscoring the significance of Castle's i

    3/3/26 4:30:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

    PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes will become effective after the market closes on Friday, December 19, 2025. The CAC Mid 60 and SBF 120 indices represent two of the most widely followed benchmarks for mid-sized and leading liste

    12/15/25 2:30:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ALVR
    $ATRA
    $BFRI
    $CDTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVR
    $ATRA
    $BFRI
    $CDTX
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will present at the Leerink Partners 2026 Global Healthcare Conference in Miami, FL on Monday, March 9, 2026, at 2:20 PM ET. A webcast replay will be available on the Events page of the Investors section of the Company's website (sentibio.com). Interested parties may access the live video webcast here. About Senti Bio Senti Bio is a biotechnolog

    3/3/26 9:05:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

    2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025."We closed out an outstanding year with a strong fourth quarter, reflecting the strength of our innovative test portfolio, disciplined execution and the dedication of the entire Castle team who continue to d

    2/26/26 4:05:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives

    - Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company's ambitions to expand its commercialisation activities and advance its innovation agenda DUBLIN, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has entered into a $25 million Standby Equity Purchase Agreement ("SEPA") with an affiliate of financing partner Yorkville Advisors Global ("Yorkville"). The agreement provides Trinity Biotech with an additional funding tool designed to augment th

    2/25/26 9:00:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care